Highlights CKD Corporation

Equities

6407

JP3346800000

Market Closed - Japan Exchange Other stock markets 11:30:00 14/05/2024 am IST			5-day change	1st Jan Change
3,240 ^JPY	-2.26%		+9.39%	+27.56%

13/05	Jefferies Adjusts CKD'S Price Target to 3,700 Yen From 4,000 Yen, Keeps at Buy	MT
15/04	AstraZeneca: expects a sharp rise in kidney disease	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AstraZeneca: expects a sharp rise in kidney disease	15/04	CF
TVS Supply Chain's Supply of CKD Kits to TVS Motor Crosses 500,000	11/04	MT
Final dividend	28/03	FA
Novo Nordisk: EU could authorize Wegovy by April	23/02	CF
Novo Nordisk: EU authorization for Wegovy by April?	23/02	CF
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia	20/02	MT
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD	31/01	MT
FDA Adds 'Boxed Warning' for Hypocalcemia Risk to Amgen's Osteoporosis Drug Prolia	19/01	MT
FDA Adds 'Boxed Warning' for Hypocalcemia Risk to Amgen's Osteoporosis Drug Prolia	19/01	MT
XORTX Submits a New Patent for the Treatment of Chronic Kidney Disease	03/01	MT
Hansoh Pharma's Three Drugs Added to China’s National Reimbursement Drug List	14/12	MT
AstraZeneca discontinues two phase III evidence trials for Lokelma	01/12	AN
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast	30/11	MT
Chong Kun Dang Pharmaceutical Inks Largest-Ever Technology Transfer Agreement with Novartis	08/11	MT
US FDA approves Ardelyx's kidney disease-related drug	18/23/18	RE
Novo Nordisk in $1.3 bln deal to buy hypertension drug	16/23/16	RE
Ex-dividend day for interim dividend	28/23/28	FA
Eli Lilly, Boehringer Ingelheim Say US FDA Approved Jardiance Tablets to Treat Adults With Chronic Kidney Disease	22/23/22	MT
Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH	06/23/06	MT
Renalytix hails KidneyIntelX inclusion in guidance to evaluate CKD	21/23/21	AN

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CKD Corporation

Equities

6407

JP3346800000

Highlights

Filters